Summary of Study ST000316
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000255. The data can be accessed directly via it's Project DOI: 10.21228/M8TG7T This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000316 |
Study Title | Comparison of Metabolites Variation and Antiobesity Effects of a Mixture of Cudrania tricuspidata, Lonicera caerulea, and the Soybean According to Fermentation in vitro and in vivo |
Study Summary | We used ultra-performance-liquid-chromatography with quadrupole-time-of-flight mass spectrometry to study the changes in metabolites in the mixture of Cudrania tricuspidata, Lonicera caerulea, and soybean (CLM) during fermentation. Additionally, the antiobesity effects of CLM and fermented-CLM (FCLM) were studied based on the analysis of plasma from high-fat diet (HFD)-fed mice. The levels of cyanidin and the glycosides of luteolin, quercetin, and cyanidin derived from L. caerulea were decreased, whereas the levels of luteolin and quercetin were increased during fermentation. Isoflavone glycosides and soyasaponins originating from the soybean were decreased, whereas their aglycones such as daidzein, glycitein, and genistein were increased. As for prenylated flavonoids from C. tricuspidata, these metabolites were decreased at the early stage of fermentation, and were increased at end of the fermentation. In terms of the functional food product, various metabolites derived from diverse natural products in CLM had complementary effects and demonstrated higher antioxidant and pancreatic lipase inhibition activities by fermentation; these activities were closely related to flavonoid aglycones including genistein, daidzein, glycitein, luteolin, and quercetin. In vivo experiment, several clinical parameters affected by HFD were remarkably improved by the administration of either CLM or FCLM, but there was a difference in the antiobesity effects. The levels of lysoPCs with C20:4, C16:0, and C22:6 were significantly attenuated by CLM administration, while the attenuated levels of lysoPCs with C20:4 and C18:2 were significantly restored by FCLM administration. These metabolites may explain the above-mentioned differences in antiobesity effects. Although only the changes in plasma lysophospholipids could not fully explain antiobesity effects between non-fermented and fermented plant mixtures from our results, we suggest that metabolomics approach could provide a way to reveal the metabolite alterations in the complex fermentation process and understand the differences or changes in bioactivity according to fermentation. |
Institute | Konkuk university |
Last Name | Suh |
First Name | Dong Ho |
Address | Neong-Dong-ro 120, Seoul, Kwang-Gin-gu, 05029, Korea, South |
sdh14031988@naver.com | |
Phone | 82-02-444-4290 |
Submit Date | 2016-01-15 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Waters) |
Analysis Type Detail | LC-MS |
Release Date | 2016-01-20 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000255 |
Project DOI: | doi: 10.21228/M8TG7T |
Project Title: | Comparison of Metabolites Variation and Antiobesity Effects of a Mixture of Cudrania tricuspidata, Lonicera caerulea, and the Soybean According to Fermentation in vitro and in vivo |
Project Summary: | We used ultra-performance-liquid-chromatography with quadrupole-time-of-flight mass spectrometry to study the changes in metabolites in the mixture of Cudrania tricuspidata, Lonicera caerulea, and soybean (CLM) during fermentation. Additionally, the antiobesity effects of CLM and fermented-CLM (FCLM) were studied based on the analysis of plasma from high-fat diet (HFD)-fed mice. The levels of cyanidin and the glycosides of luteolin, quercetin, and cyanidin derived from L. caerulea were decreased, whereas the levels of luteolin and quercetin were increased during fermentation. Isoflavone glycosides and soyasaponins originating from the soybean were decreased, whereas their aglycones such as daidzein, glycitein, and genistein were increased. As for prenylated flavonoids from C. tricuspidata, these metabolites were decreased at the early stage of fermentation, and were increased at end of the fermentation. In terms of the functional food product, various metabolites derived from diverse natural products in CLM had complementary effects and demonstrated higher antioxidant and pancreatic lipase inhibition activities by fermentation; these activities were closely related to flavonoid aglycones including genistein, daidzein, glycitein, luteolin, and quercetin. In vivo experiment, several clinical parameters affected by HFD were remarkably improved by the administration of either CLM or FCLM, but there was a difference in the antiobesity effects. The levels of lysoPCs with C20:4, C16:0, and C22:6 were significantly attenuated by CLM administration, while the attenuated levels of lysoPCs with C20:4 and C18:2 were significantly restored by FCLM administration. These metabolites may explain the above-mentioned differences in antiobesity effects. Although only the changes in plasma lysophospholipids could not fully explain antiobesity effects between non-fermented and fermented plant mixtures from our results, we suggest that metabolomics approach could provide a way to reveal the metabolite alterations in the complex fermentation process and understand the differences or changes in bioactivity according to fermentation. |
Institute: | Konkuk university |
Last Name: | Suh |
First Name: | Dong Ho |
Address: | Neong-Dong-ro 120, Seoul, Kwang-Gin-gu, 05029, Korea, South |
Email: | sdh14031988@naver.com |
Phone: | 82-02-444-4290 |
Subject:
Subject ID: | SU000336 |
Subject Type: | Animal |
Subject Species: | Mus musculus |
Taxonomy ID: | 10090 |
Species Group: | Mammals |
Factors:
Subject type: Animal; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | Diet |
---|---|---|
SA014424 | HCLM7 | HCLM |
SA014425 | HCLM10 | HCLM |
SA014426 | HCLM9 | HCLM |
SA014427 | HCLM5 | HCLM |
SA014428 | HCLM8 | HCLM |
SA014429 | HCLM6 | HCLM |
SA014430 | HCLM1 | HCLM |
SA014431 | HCLM3 | HCLM |
SA014432 | HCLM2 | HCLM |
SA014433 | HCLM4 | HCLM |
SA014434 | HD8 | HD |
SA014435 | HD9 | HD |
SA014436 | HD10 | HD |
SA014437 | HD7 | HD |
SA014438 | HD5 | HD |
SA014439 | HD1 | HD |
SA014440 | HD6 | HD |
SA014441 | HD3 | HD |
SA014442 | HD2 | HD |
SA014443 | HD4 | HD |
SA014444 | HFCLM5 | HFCLM |
SA014445 | HFCLM6 | HFCLM |
SA014446 | HFCLM7 | HFCLM |
SA014447 | HFCLM4 | HFCLM |
SA014448 | HFCLM1 | HFCLM |
SA014449 | HFCLM3 | HFCLM |
SA014450 | HFCLM2 | HFCLM |
SA014451 | HX10 | HX |
SA014452 | HX4 | HX |
SA014453 | HX3 | HX |
SA014454 | HX2 | HX |
SA014455 | HX9 | HX |
SA014456 | HX5 | HX |
SA014457 | HX1 | HX |
SA014458 | HX7 | HX |
SA014459 | HX8 | HX |
SA014460 | HX6 | HX |
SA014461 | ND5 | ND |
SA014462 | ND4 | ND |
SA014463 | ND2 | ND |
SA014464 | ND6 | ND |
SA014465 | ND3 | ND |
SA014466 | ND8 | ND |
SA014467 | ND10 | ND |
SA014468 | ND9 | ND |
SA014469 | ND1 | ND |
SA014470 | ND7 | ND |
Showing results 1 to 47 of 47 |
Collection:
Collection ID: | CO000330 |
Collection Summary: | Plasma 200uL were extracted with 1mL of 80% MeOH |
Sample Type: | Blood |
Treatment:
Treatment ID: | TR000350 |
Treatment Summary: | Seven-week-old C57BL6J male mice were purchased from Daehan bio-link (Chungbuk, Republic of Korea). All mice were acclimated for 1 week under controlled conditions (temperature: 25 ± 2°C, relative humidity: 50 ± 5%, and 12 h light/dark cycle). The animals had free access to a normal diet (AIN-76A, Research Diets, Inc., NJ, USA) and water. After 1 week, the mice were randomly distributed into 5 groups: (1) group normal-diet (ND) (n = 11) was fed a normal diet for 6 weeks, (2) group HFD (named HD; n = 10) was fed 60 kcal% fat (D1242, Research Diets, Inc., NJ, USA) for 6 weeks, (3) group HFD with xenical administration (HX, 50 mg?kg?1?day?1) n = 10, 6 weeks, (4) group HFD with CLM administration (HCLM, 2 g?kg?1?day?1) n = 10, 6 weeks; and (5) group HFD with FCLM (CLM fermented for 60 h) administration (HFCLM, 2 g?kg?1?day?1) n = 8, 6 weeks. In this study, we used xenical as a positive control for antiobesity effects. Xenical, CLM, and FCLM dissolved with saline were orally administered everyday into the stomach with an oral zonde needle. And, the equal volume of saline were applied for ND and HD groups. During the experimental periods, the feed intake and the body weight of the mice were measured daily. |
Treatment Protocol Filename: | DongHo_20160115_025706_PR_CO_The_animal_experiment.docx |
Sample Preparation:
Sampleprep ID: | SP000344 |
Sampleprep Summary: | For blood collection, the mice were sacrificed by cardiac puncture. Plasma (100 µL) was subjected to extraction with cold methanol (500 µL) on a MM400 mixer mill (Retsch®, Haan, Germany) with the frequency 30 s?1 for 5 min. The suspension was centrifuged at 12,578 g for 10 min at 4°C. The supernatant was filtered through a 0.2-µm PTEE filter and evaporated in a speed vacuum concentrator. The final concentration of the plasma was 5 mg/mL in methanol for the UPLC-Q-TOF-MS analysis. |
Combined analysis:
Analysis ID | AN000502 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Waters Acquity |
Column | Waters Acquity BEH C18 (100 x 2mm,1.7um) |
MS Type | ESI |
MS instrument type | QTOF |
MS instrument name | Waters Micromass QTOF Premier |
Ion Mode | POSITIVE |
Units | Peak area |
Chromatography:
Chromatography ID: | CH000354 |
Instrument Name: | Waters Acquity |
Column Name: | Waters Acquity BEH C18 (100 x 2mm,1.7um) |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS000438 |
Analysis ID: | AN000502 |
Instrument Name: | Waters Micromass QTOF Premier |
Instrument Type: | QTOF |
MS Type: | ESI |
Ion Mode: | POSITIVE |